The Consensus Report ADA-EASD 2022 recommends SGLT-2i or GLP-1 RA as first-line therapy, irrespective of the use of metformin, in addition to medical nutrition therapy (MNT) to reduce the cardio-renal risk in high-risk patients with T2DM [3]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.